Drug intelligence / Profile preview

RS-015

Development stage: Preclinical
Lead developer: Related Sciences

Overview

RS-015 is a preclinical-stage drug candidate being developed by Related Sciences, through its portfolio company Danger Bio, for the treatment of autoimmune and inflammatory diseases. The program is currently in the late discovery phase of preclinical development. As part of Danger Bio's broader portfolio, which targets the immune system's danger response and innate immunity pathways, specific details regarding the molecular target and modality of RS-015 have not been publicly disclosed.

Beyond the preview

Go deeper on RS-015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS-015.

Explore the full profile